Amanda Peltier, MD
Neuromuscular Medicine · Nashville, TNNPI 1093802126
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 25.7% of the total. Reporting peaked in 2019 at $85,786 and has fallen 78.7% since, to $18,280 in 2025.
Across 304 payments — averaging $771.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$60K
- Akcea Therapeutics, Inc.$56K
- AstraZeneca$55K
- Catalyst Pharmaceuticals, Inc.$33K
- CSL Behring$21K
- Astrazeneca UK Limited$6K
- plus $3K from 6 others
Across 56 payments — averaging $11,690 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$342K
- Alnylam Pharmaceuticals Inc.$117K
- AstraZeneca$51K
- Argenx US, Inc.$44K
- Novartis$36K
- Biohaven Pharmaceutical Holding Company Ltd.$33K
- plus $32K from 2 others
What the payments were for
- Consulting fees$87,53137%
- Speaking & faculty fees$98,10542%
- Travel & lodging$37,05716%
- Food & beverage$11,6645%
- Education$1480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 82 | $60,308 |
| Akcea Therapeutics, Inc. | 78 | $55,952 |
| AstraZeneca(2 entities) | 59 | $54,510 |
| Catalyst Pharmaceuticals, Inc. | 30 | $33,211 |
| CSL Behring | 29 | $20,803 |
| Astrazeneca UK Limited | 2 | $6,444 |
| Argenx US, Inc. | 18 | $3,020 |
| Johnson & Johnson | 2 | $130 |
| Pfizer | 1 | $73 |
| Amgen | 1 | $21 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few neuromuscular medicine providers in Tennesseeto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FirdapseAmifampridine Phosphate | 23 | $1,157,203 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 35 | $624,291 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 25 | $586,701 |
| WainuaEplontersen Sodium | 12 | $507,069 |
| OnpattroPatisiran Sodium,lipid Complex | 15 | $305,292 |
| Radicava OrsEdaravone | 22 | $301,434 |
| Droxidopa | 122 | $72,726 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $18,024 |
| Midodrine Hcl | 31 | $5,212 |
| Pyridostigmine Bromide | 43 | $4,681 |
| Gabapentin | 139 | $4,445 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 14 | $4,419 |
| Pregabalin | 135 | $3,967 |
| Mycophenolate Mofetil | 13 | $2,465 |
| Atomoxetine Hcl | 18 | $1,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Catalyst Pharmaceuticals, Inc.Firdapse | $33,211 | $1,157,20323 claims |
| CSL BehringPrivigen | $20,803 | $586,70125 claims |
| AstraZenecaWainua | $54,510 | $507,06912 claims |
| Alnylam Pharmaceuticals Inc.Onpattro | $60,308 | $305,29215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in Tennesseeon file to place this against a meaningful peer group, so we don't.
Other neuromuscular medicine in Nashville
- Peter DonofrioNashville$47K
- Lindsay MalatestaNashville$24K
- Stephen LayfieldNashville$2K
- Madhura LayfieldNashville$2K
- John SturgisNashville$1K
- Christopher LeeNashville$379
- Lauren HerreraNashville$69
- Joshua AlpersChattanooga$623K
- Daniel Guillen MendozaMemphis$65K
- Elena CaronMemphis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.